Post-Operative Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

No Publisher
281 Pages - GMD18340
$2,500.00

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Operative Pain - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Post-Operative Pain (Central Nervous System) pipeline landscape.

Pain is one of the main postoperative adverse outcomes causing distress to patients. Degree of postoperative pain experienced by individuals varies. Cause of pain includes peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Operative Pain - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Post-Operative Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Operative Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 12, 34, 13, 5, 41, 1 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Unknown stages comprise 1, 1, 3 and 1 molecules, respectively.

Post-Operative Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Operative Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Post-Operative Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post-Operative Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post-Operative Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post-Operative Pain (Central Nervous System)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Operative Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Operative Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

'

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Post-Operative Pain - Overview
Post-Operative Pain - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Post-Operative Pain - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Post-Operative Pain - Companies Involved in Therapeutics Development
Post-Operative Pain - Drug Profiles
Post-Operative Pain - Dormant Projects
Post-Operative Pain - Discontinued Products
Post-Operative Pain - Product Development Milestones
Featured News & Press Releases
Mar 21, 2022: Cali Biosciences announces successful results in phase IIb study of long-acting ropivacaine (CPL-01) for non-opioid treatment of post-operative pain
Feb 02, 2022: Concentric analgesics forges important phase 3 clinical relationships for Vocacapsaicin, a non-opioid pain therapy targeting TRPV1 receptor
Feb 01, 2022: AcelRx Pharmaceuticals announces publication of clinical data on the use of sufentanil sublingual tablet during awake plastic surgery procedures
Jan 28, 2022: Jiangsu Enhua Pharmaceutical announcement on obtaining the notification of acceptance of application for marketing authorization of Oxelidine Fumarate Injection (TRV130)
Jan 27, 2022: AcelRx Pharmaceuticals announces publication of an article highlighting the utility of the sufentanil sublingual tablet in pain medicine procedures
Jan 12, 2022: AcelRx Pharmaceuticals announces publication of an editorial by an internationally recognized leader in opioid-sparing surgery highlighting the potential advantages of the sufentanil sublingual tablet in joint replacement surgery
Dec 15, 2021: AcelRx Pharmaceuticals announces publication of clinical data showing reduced hospital length of stay and reduced opioid utilization with use of sublingual sufentanil in total joint replacement surgery
Nov 22, 2021: Concentric Analgesics announces poster presentation of positive vocacapsaicin data from total knee arthroplasty phase 2 study at the 2021 American Academy of Hip and Knee Surgeons Annual Meeting
Nov 19, 2021: ASRA 2021: Cali Biosciences presents Phase IIa clinical data on CPL-01, a long-acting Ropivacaine
Nov 16, 2021: LT1001 formulation patent granted by JPO
Nov 15, 2021: Hyloris announces earlier than expected PDUFA date for Maxigesic IV
Nov 08, 2021: Pacira files lawsuit against eVenus for patent infringement
Nov 02, 2021: Pacira receives notice of allowance for new patent covering EXPAREL composition
Nov 01, 2021: Hyloris announces FDA acceptance of New Drug Application for Maxigesic IV in post-operative pain
Oct 28, 2021: InSitu Biologics INSB200 poster chosen “Best of Meeting” at American Society of Regional Anesthesia Pain Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Post-Operative Pain, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Companies, 2022 (Contd..3)
Number of Products under Development by Companies, 2022 (Contd..4)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Target, 2022 (Contd..2)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Post-Operative Pain - Pipeline by Acadia Pharmaceuticals Inc, 2022
Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals Inc, 2022
Post-Operative Pain - Pipeline by Adare Pharma Solutions, 2022
Post-Operative Pain - Pipeline by Algomedix Inc, 2022
Post-Operative Pain - Pipeline by Allay Therapeutics Inc, 2022
Post-Operative Pain - Pipeline by Altus Formulation Inc, 2022
Post-Operative Pain - Pipeline by AmacaThera Inc, 2022
Post-Operative Pain - Pipeline by Andros Pharmaceuticals Co Ltd, 2022
Post-Operative Pain - Pipeline by AngioChem Inc, 2022
Post-Operative Pain - Pipeline by Antibe Therapeutics Inc, 2022
Post-Operative Pain - Pipeline by Bayer AG, 2022
Post-Operative Pain - Pipeline by Beijing Join Chain Medicine Co Ltd, 2022
Post-Operative Pain - Pipeline by Benuvia Therapeutics Inc, 2022
Post-Operative Pain - Pipeline by Brainfarma Chemical and Pharmaceutical Industry SA, 2022
Post-Operative Pain - Pipeline by Cali Pharmaceuticals LLC, 2022
Post-Operative Pain - Pipeline by Camurus AB, 2022
Post-Operative Pain - Pipeline by Cara Therapeutics Inc, 2022
Post-Operative Pain - Pipeline by Cellix Bio Pvt Ltd, 2022
Post-Operative Pain - Pipeline by Chromocell Corp, 2022
Post-Operative Pain - Pipeline by Clexio Biosciences Ltd, 2022
Post-Operative Pain - Pipeline by Concentric Analgesics Inc, 2022
Post-Operative Pain - Pipeline by Cytogel Pharma LLC, 2022
Post-Operative Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Post-Operative Pain - Pipeline by Dompe Farmaceutici SpA, 2022
Post-Operative Pain - Pipeline by Douleur Therapeutics Inc, 2022
Post-Operative Pain - Pipeline by Eliem Therapeutics Inc, 2022
Post-Operative Pain - Pipeline by Ethismos Research Inc, 2022
Post-Operative Pain - Pipeline by Euclises Pharmaceuticals Inc, 2022
Post-Operative Pain - Pipeline by Eupraxia Pharmaceuticals Inc, 2022
Post-Operative Pain - Pipeline by Eurofarma Laboratorios SA, 2022
Post-Operative Pain - Pipeline by Flexion Therapeutics Inc, 2022
Post-Operative Pain - Pipeline by Fujimoto Pharmaceutical Corp, 2022
Post-Operative Pain - Pipeline by G2GBIO Inc, 2022
Post-Operative Pain - Pipeline by Grunenthal GmbH, 2022
Post-Operative Pain - Pipeline by Guangdong Jiabo Pharmaceutical Co Ltd, 2022
Post-Operative Pain - Pipeline by Hana Pharm Co Ltd, 2022
Post-Operative Pain - Pipeline by Hefei Cosource Pharmaceutical Inc, 2022
Post-Operative Pain - Pipeline by Heron Therapeutics Inc, 2022
Post-Operative Pain - Pipeline by Hyloris Pharmaceuticals SA, 2022
Post-Operative Pain - Pipeline by IACTA Pharmaceuticals Inc, 2022
Post-Operative Pain - Pipeline by InSitu Biologics LLC, 2022
Post-Operative Pain - Pipeline by Insys Therapeutics Inc (Inactive), 2022
Post-Operative Pain - Pipeline by InterK Peptide Therapeutics Ltd, 2022
Post-Operative Pain - Pipeline by Ionis Pharmaceuticals Inc, 2022
Post-Operative Pain - Pipeline by iX Biopharma Ltd, 2022
Post-Operative Pain - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Post-Operative Pain - Pipeline by Jiangsu Huatai Chenguang Pharmaceutical Co Ltd, 2022
Post-Operative Pain - Pipeline by Liquidia Technologies Inc, 2022
Post-Operative Pain - Pipeline by Lumosa Therapeutics Co Ltd, 2022
Post-Operative Pain - Pipeline by Luye Pharma Group Ltd, 2022
Post-Operative Pain - Pipeline by Medical Developments International Ltd, 2022
Post-Operative Pain - Pipeline by MedinCell SA, 2022
Post-Operative Pain - Pipeline by Mundipharma International Ltd, 2022
Post-Operative Pain - Pipeline by Nang Kuang Pharmaceutical Co Ltd, 2022
Post-Operative Pain - Pipeline by Nanjing Delova Biotech Co Ltd, 2022
Post-Operative Pain - Pipeline by Nanjing Heron Pharmaceutical Science and Technology Co Ltd, 2022
Post-Operative Pain - Pipeline by Neumentum Inc, 2022
Post-Operative Pain - Pipeline by Neurocarrus Inc, 2022
Post-Operative Pain - Pipeline by NeuroPn Therapeutics LLC, 2022
Post-Operative Pain - Pipeline by Nevakar Injectables Inc, 2022
Post-Operative Pain - Pipeline by Ocular Therapeutix Inc, 2022
Post-Operative Pain - Pipeline by Pacira BioSciences Inc, 2022
Post-Operative Pain - Pipeline by PainReform Ltd, 2022
Post-Operative Pain - Pipeline by Pharmazz Inc, 2022
Post-Operative Pain - Pipeline by PhytoHealth Corp, 2022
Post-Operative Pain - Pipeline by PolyPid Ltd, 2022
Post-Operative Pain - Pipeline by Revogenex Inc, 2022
Post-Operative Pain - Pipeline by RHNanopharmacuticals LLC, 2022
Post-Operative Pain - Pipeline by Rottapharm Biotech Srl, 2022
Post-Operative Pain - Pipeline by Sedor Pharmaceuticals LLC, 2022
Post-Operative Pain - Pipeline by Seelos Therapeutics, Inc., 2022
Post-Operative Pain - Pipeline by Serina Therapeutics Inc, 2022
Post-Operative Pain - Pipeline by Shijiazhuang Yiling Pharmaceutical Co Ltd, 2022
Post-Operative Pain - Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, 2022
Post-Operative Pain - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022
Post-Operative Pain - Pipeline by SiteOne Therapeutics Inc, 2022
Post-Operative Pain - Pipeline by Sonoran Biosciences Inc, 2022
Post-Operative Pain - Pipeline by Sotex Pharm Firm, 2022
Post-Operative Pain - Pipeline by Stragen New Molecules, 2022
Post-Operative Pain - Pipeline by Taiwan Liposome Co Ltd, 2022
Post-Operative Pain - Pipeline by Teikoku Pharma USA Inc, 2022
Post-Operative Pain - Pipeline by Theracaine LLC, 2022
Post-Operative Pain - Pipeline by Trevena Inc, 2022
Post-Operative Pain - Pipeline by Tris Pharma Inc, 2022
Post-Operative Pain - Pipeline by Vertex Pharmaceuticals Inc, 2022
Post-Operative Pain - Pipeline by Viatris Inc, 2022
Post-Operative Pain - Pipeline by Virpax Pharmaceuticals Inc, 2022
Post-Operative Pain - Pipeline by Vivozon Inc, 2022
Post-Operative Pain - Pipeline by Xgene Pharmaceutical Inc, 2022
Post-Operative Pain - Pipeline by Xigen SA, 2022
Post-Operative Pain - Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2022
Post-Operative Pain - Dormant Projects, 2022
Post-Operative Pain - Dormant Projects, 2022 (Contd..1)
Post-Operative Pain - Dormant Projects, 2022 (Contd..2)
Post-Operative Pain - Dormant Projects, 2022 (Contd..3)
Post-Operative Pain - Dormant Projects, 2022 (Contd..4)
Post-Operative Pain - Discontinued Products, 2022

List of Figures
Number of Products under Development for Post-Operative Pain, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838